Since the discovery of calbindin D9k, its role in intestinal calcium absorption has remained unsettled. Further, a wide distribution of calbindin D 9k among tissues has argued for its biological importance. We discovered a frameshift deletion in the calbindin D 9k gene in an ES cell line, E14.1, that originated from 129͞OlaHsd mice. We produced mice with the mutant calbindin D9k gene by injecting the E14.1 ES cell subline into the C57BL͞6 host blastocysts and proved that these mice lack calbindin D 9k protein. Calbindin D9k knockout mice were indistinguishable from wild-type mice in phenotype, were able to reproduce, and had normal serum calcium levels. Thus, calbindin D 9k is not required for viability, reproduction, or calcium homeostasis.
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vitamin D 3 ͉ E14ES cells ͉ calcium homeostasis F or decades, a major physiologic function of calbindin D 9k was believed to be a carrier of calcium during intestinal calcium absorption (1) . However, the detailed mechanism of vitamin D-induced intestinal calcium absorption still is not fully understood. According to the currently accepted model, vitamin D-mediated transcellular calcium absorption in the intestine proceeds through the calcium channel proteins TRPV5 and TRPV6 (2) with the involvement of cellular calcium transfer protein calbindin D 9k (1, 3) and a calcium extrusion protein, calcium ATPase (PMCA 1b ) (4) . The data on regulation of epithelial calcium channels (TRPV5 and TRPV6), calbindin D 9k , and PMCA 1b expression by 1,25-dihydroxyvitamin D 3 seem clear, and these genes have vitamin D responsive elements in their promoter regions (5) (6) (7) .
Calbindin D 9k was first discovered as the mammalian counterpart to the calbindin D 28k that was found in chick duodenal mucosa in response to vitamin D 3 (8, 9) . Later, calbindin D 9k from vitamin D 3 -responsive rat intestinal mucosa was identified, purified, and characterized (9, 10) . Since its discovery in 1967, the role of calbindin D 9k protein in vitamin D 3 -mediated intestinal calcium absorption has been intensively studied but still remains unsettled. In the meantime, a wide distribution of this protein in tissues not involved in calcium absorption has been noted, arguing for its importance in biology (11) (12) (13) .
In 1969, Harmeyer and DeLuca (14) provided evidence that calcium absorption and calbindin D 9k levels in response to vitamin D 3 are not directly related. Similar discrepancies were reported by others (15) . Additional doubts concerning the role of calbindin D 9k in calcium transport appeared after studies in vitamin D receptor knockout mice (16, 17) . The absence of a calbindin D 9k -mediated mechanism for active Ca 2ϩ transport was also shown in sheep rumen (18 
Results and Discussion
Discovery of the Mutant Mouse Calbindin D9k Gene. The P1 clone 7681 with an 85-kb insert of genomic DNA͞SauIIIA containing the mouse calbindin D 9k gene was purchased from Incyte Genomics (Palo Alto, CA). The P1 mouse library was generated by Sternberg et al. (20) by using genomic DNA from the ES cell line subclone E14.1, which is derived from E14 ES cells (21) . The ES cell line E14 was derived from the inbred mouse strain 129͞OlaHsd in 1985 by Hooper et al. (22) . The insert was cut with BamHI and subcloned into pBluescript (Stratagene, La Jolla, CA). The clone that was positive for the calbindin D 9k gene was selected by Northern blot analysis, and a plasmid with the mutant calbindin D 9k insert was isolated. We have sequenced the 10.409-kb insert containing the calbindin D 9k gene and compared it with the 8.434 kb of deposited sequence of the calbindin D 9k gene of mouse strain ICRxSwiss (GenBank accession no. AY034822). Both sequences overlap in the calbindin D 9k gene region, but our sequence is 2,111 bp downstream of the AY034822 sequence. Both sequences seemed to be 98-99% identical, with a few gaps in noncoding regions. The major difference we discovered in the calbindin D 9k gene sequence was the deletion of 22 nt in exon III compared with AY034822 ( Fig.  1 ). This deletion resulted in a frameshift, thereby creating a new in-frame stop codon 63 nt downstream of the original stop codon (Fig. 1) , which could generate a hypothetical mutant calbindin D 9k protein that would be 21 aa longer than the native protein.
The deduced mutant protein should be 100 aa long, with a molecular weight of 11,363 and a theoretical pI of 9.07 with a total of 14 negatively charged residues (Asp plus Glu) and a total of 17 positively charged residues (Arg plus Lys). The wild-type protein is 79 aa, with a molecular weight of 8,970 and a theoretical pI of 4.69 with a total of 16 negatively charged residues (Asp plus Glu) and a total of 11 positively charged residues (Arg plus Lys). We aligned sequences of the wild-type protein and the deduced mutant calbindin D 9k protein (Fig. 2) . Both proteins are identical in the first 51 aa and have no similarity after that. Wild-type calbindin D 9k protein, as a Ca 2ϩ -binding protein, has two EF hands and is acidic (23), whereas the mutant calbindin D 9k is missing the second EF hand and is basic. We assumed that this protein might not exist in vivo, as was shown for caspase 3 (24) , so mice with this mutant calbindin D 9k gene could potentially be calbindin D 9k null.
Generation of Mutant Calbindin D9k Gene Mice. We first checked whether the original 129͞OlaHsd mice, which were the source of the ES cell line E14.1, have the same 22-nt deletion in the calbindin D 9k gene, but they did not. We checked several other 129 mouse substrains, and all of them had the wild-type calbindin D 9k genotype. So the only source of the mutant calbindin D 9k gene was the ES cell subclone E14.1.
We generated mice with the mutant calbindin D 9k gene by injection of the E14.1 ES cell subline into C57BL͞6 host blastocysts as described in Materials and Methods. Chimeric males were bred to 129͞OlaHsd females to generate an inbred 129͞OlaHsd line that was homozygous for the mutant calbindin D 9k gene with a 22-nt deletion in exon III as was confirmed by genotyping.
Mutant Calbindin D9k
Mice Have the Knockout Phenotype. Mice homozygous for the mutant calbindin D 9k gene (22 nt deleted in exon III) were generated and mRNA analyzed by RT-PCR. For this, we used primers flanking the entire coding region of the calbindin D 9k gene. These primers (see Materials and Methods) amplified a 418-bp product from wild-type mice and a 396-bp product from the mutant mice. As expected, no full-length product (418 bp) was detected in mutant calbindin D 9k mice. Both products were sequenced to confirm the specificity of the amplification. Sequencing data revealed that the PCR product obtained from the mRNA of mutant mice had the identical 22-bp deletion detected in exon III of the mutant calbindin D 9k gene.
To determine whether either the mutant or wild-type calbindin D 9k protein could be detected in the mutant mouse duodenum lysate, we used all available antibodies. Western blot analysis was carried out by using duodenal lysates from the wild-type and mutant mice. As shown in Fig. 3A , an antibody raised against the full-length calbindin D 9k protein (1-79 aa) recognized a 9-kDa band in the wild type; however, neither a 9-kDa band (wild-type protein) nor an 11.3-kDa (mutant protein) band was detected in the mutant mice duodenal lysates. The antibody to the common segment (1-60 aa) of both wild-type and putative mutant calbindin D 9k proteins detected the wildtype protein band but failed to detect either of these bands in the mutant duodenal lysate (Fig. 3B) .
To be sure that the mutant calbindin D 9k protein is not expressed in mutant mice, we expressed the mutant protein in Escherichia coli, purified it to homogeneity, and produced antibodies to the mutant calbindin D 9k protein. Using this antibody, no mutant calbindin D 9k protein was found in mutant mice duodenal lysates, whereas this antibody clearly showed calbindin D 9k in the lysates of wild-type mice (Fig. 3C) .
These results clearly demonstrate that putative mutant calbindin D 9k protein does not exist in the mutant mouse despite the presence of its mRNA, thus confirming that the mouse that is homozygous for the mutant calbindin D 9k gene is a calbindin D 9k null mouse.
Calbindin D9k Knockout Mice Phenotype and Serum Calcium Level.
The calbindin D 9k knockout mice do not exhibit any overt phenotypic abnormalities: specifically, no skeletal abnormalities were detected. They grow and develop normally; the growth rate of the weanlings is comparable to that of the wild type as assessed by their weekly weight gain. Their life expectancy also does not differ from the wild type. Calbindin D 9k knockout mice retain similar fertility to the wild-type mice and are fully able to reproduce. The average size of the litter from the knockout is comparable to that of wild type as well. To find out whether the lack of calbindin D 9k protein in the knockout mice results in any effect on calcium homeostasis, serum calcium levels of the knockout and wild-type mice kept on a chow diet were monitored from 4 weeks of age to adulthood (Fig. 4) . The data show that the serum calcium levels of the knockout and the wild-type mice are identical over the extended period investigated in both male and female mice.
Thus, we generated mice lacking the calbindin D 9k protein and demonstrated that knockout mice are indistinguishable from wild type in phenotype and are able to maintain normal serum calcium levels in the absence of calbindin D 9k protein, regardless of age or sex. Although a direct assessment of whether the intestine lacking the calbindin D 9k protein can respond to 1,25-dihydroxyvitamin D 3 by increasing calcium absorption has not yet been examined, the fact that serum calcium is normal in knockout mice suggests that calbindin D 9k is not required for vitamin D-induced calcium absorption. This belief is supported by the fact that vitamin D receptor null mice are hypocalcemic under these circumstances (25) . Mice. 129͞OlaHsd mice were purchased from Harlan (Indianapolis, IN). Animals were maintained and research was conducted in accordance with guidelines set forth by the Animal Care and Research Committee of University of Wisconsin.
Materials and Methods
Identity of the 129͞Ola Calbindin D9k Gene. The sequence was established by sequencing the DNA on an LKB ALF DNA sequencer (GE Healthcare Bio-Sciences, Piscataway, NJ) by using the Thermo sequenase fluorescent-labeled primer-cycle sequencing kit (GE Healthcare Bio-Sciences) at the University of Wisconsin Biotechnology Center DNA Synthesis͞Sequencing Facility, using the set of 20 primers designed for each direction. Computer analysis of the sequence was performed with the Sequence Analysis Software Package from Genetics Computer Group (Madison, WI).
Generation of Mutant Calbindin D9k
Mice. The E14.11C ES cell subline was injected into C57BL͞6 host blastocysts at the University of Wisconsin Biotechnology Center Transgenic Animal Facility. ES cells were grown for 3-4 days on a leukemia inhibitory factor-producing feeder layer. ES cells were disaggregated into a single-cell suspension, separated from the feeder cells, and injected into the blastocoel cavities of expanded C57BL͞6 blastocysts. After the microinjections, the blastocysts were allowed to recover and transferred into the oviducts of pseudopregnant recipients. Potential founder pups were born 19 days later, and coat color was identified 1 week later. The 129͞OlaHsd ES cells were from an agouti strain, and the blastocysts were from a black strain. Nine males with a high percentage of agouti hair were produced.
Three founder chimeras were mated to C57BL͞6 partners at 6-7 weeks of age. All three founders produced agouti pups, indicating that the injected ES cells contributed to the formation of the germ line in the founder animals. Agouti F1 pups were genotyped by PCR.
Chimeric males were bred to 129͞OlaHsd females (Harlan) to generate an inbred 129͞Ola line. All female F1 pups were heterozygous for the calbindin D 9k deletion. The heterozygous pups were backcrossed to founder males to generate female mice that were homozygous for the calbindin D 9k gene with deletion.
Genotyping of Calbindin D9k Knockout Mice. Genomic DNA was extracted from mouse tails by using a Puregene DNA isolation kit (mouse tail kit, Gentra Systems, Minneapolis, MN). To distinguish the wild-type allele from mutant alleles, a separate set of primers was designed for each allele. For the wild-type allele, the downstream primer was designed within the 22-bp deletion region of exon III of the calbindin gene. Because the mutant allele lacks this 22-bp region, this primer is unable to bind to the mutant allele. On the other hand, the downstream primer for the mutant allele was designed for only the flanking region of the deletion. The sequence of the primer covers part of the left border and part of the right border of the deletion. Therefore, the mutant downstream primer was unable to bind to the wild-type allele for PCR. The upstream primers were also designed for different regions of the gene upstream. The oligonucleotide primers designed for the wild-type allele were as follows: upstream, 5Ј-GAT CAT AGT GGG TTT CAG G-3Ј; downstream, 5Ј-ATC GCC ATT CTT ATC CAG-3Ј. The oligonucleotide primers designed for the mutant allele were as follows: upstream, 5Ј-CAC CCC ACC GAC CAT CAG-3Ј; downstream, 5Ј-ATC GCC ATT CTG TCC AGA GT-3Ј. The size of the wild-type PCR product is 324 bp, and the mutant PCR product is 189 bp.
Two separate PCRs were run for genomic DNA extracted from each mouse. One reaction was run with primer sets designed for wild-type alleles and another reaction was run with primer sets designed for mutant alleles. PCRs were performed by using the Advantage cDNA Polymerase Mix from Clontech Laboratories (Mountain View, CA). The parameters for PCR were as follows: initial denaturation at 94°C for 4 min followed by 29 cycles at 94°C for 30 s, 64°C for 40 s, and 72°C for 2 min. Final extension of the DNA was done for 5 min at 72°C. PCR was performed by using the Programmable Thermal Cycler PTC 100 (MJ Research, now Global Medical Instrumentation, Ramsey, MN). The PCR products were visualized on a 1.3% agarose gel run in 1XTAE after staining with ethidium bromide.
Intestinal Homogenate Preparation for mRNA Isolation. The first 5 cm of intestine (the duodenum) was removed, slit open longitudinally, and scraped with a glass slide to remove mucosa. The mucosa was homogenized with a PowerGen 700 (Fisher Scientific, Pittsburgh, PA) in guanidine thiocyanate extraction buffer supplemented with 2% 2-mercaptoethanol (PolyATtract System 1000, Promega, Madison, WI), flash-frozen in liquid N 2 , and stored at Ϫ80°C. mRNA Isolation. Poly(A ϩ ) RNA was isolated from homogenized mucosa by using a PolyATtract System 1000 (Promega) and purified by using an RNeasy kit (Qiagen, Chatsworth, CA). The quality, integrity, and quantity of the poly(A ϩ ) RNA were determined by agarose gel electrophoresis and UV absorption spectrophotometry.
Reverse Transcription and DNA Amplification by PCR. Reverse transcription of intestinal poly(A) ϩ RNA and subsequent DNA amplification was carried out by using a GeneAmp Gold RNA PCR reagent kit from Applied Biosystems (Foster City, CA) according to the conditions recommended by the manufacturer. The oligonucleotide primers used for DNA amplification were as follows: sense (upstream), 5Ј-CCT GCT GTT CCT GTC TGA-3Ј; antisense (downstream), 5Ј-CGT GTC TCC GAA CTT GCT TTA T-3Ј. The primers were designed to flank the entire coding region of the mRNA. The RT-PCR was performed on a Programmable Thermal Cycler PTC 100 (Global Medical Instrumentation). After amplification by PCR, the DNA reaction products were analyzed on 1.4% agarose gel after staining with ethidium bromide. The sequencing of the PCR product was carried out with an LKB ALF DNA sequencer (GE Healthcare Bio-Sciences) by using the Thermo sequenase fluorescentlabeled primer-cycle sequencing kit (GE Healthcare BioSciences). Computer analysis of the sequence was performed by using the Sequence Analysis Software Package from Genetics Computer Group.
Construction of Plasmid with Mutant Calbindin D9k cDNA Sequence. In the mutant calbindin D 9k cDNA produced by RT-PCR as described above, restriction sites NdeI and BamHI were incorporated into the 5Ј and 3Ј sites, respectively. The NdeI site was located upstream of mutant calbindin D 9k cDNA, and the BamHI site was located right after the stop codon. Using the generated restriction sites, mutant calbindin D 9k cDNA was subcloned into the expression vector pET-14b (Novagen͞EMD Biosciences, Madison, WI). This construct was transfected into XL-1 Blue Cells (Stratagene). The plasmid with the mutant calbindin D 9k cDNA, p14D9Kmt, was isolated, and the sequence of mutant calbindin D 9k cDNA was confirmed. In this construct, the mutant calbindin D 9k was expressed as protein with the N-terminal His-tag sequence along with a thrombin cleavage site that was present between the His-tag and start of mutant calbindin D 9k protein sequence.
Expression of Mutant Calbindin D9k
Protein and E. coli Lysate Preparation. The p14D9Kmt was transfected into BL21-CodonPlus (DE3)-RIPL Competent Cells (Stratagene) to express the mutant calbindin D 9k according to manufacturer's protocol. Cells were grown at 37°C, and the expression of the protein was induced at room temperature by 50 ⌴ isopropyl ␤-Dthiogalactoside. E. coli cells were harvested 6 h later and lysed as follows. Cells (7.7 g) were added to 25 ml of lysis buffer containing 50 mM Tris⅐HCl (pH 8), 0.5 M NaCl, 20 mM imidazole, 0.02% sodium azide, 10 mM 2-mercaptoethanol, 20% glycerol, 1 mM PMSF, 1% Triton X-100, and one Complete, EDTA-Free Protease Inhibitor Mixture Tablet (Roche Diagnostics, Mannheim, Germany). The 2-mercaptoethanol, PMSF, Complete, EDTA-Free Protease Inhibitor Mixture Tablet, and Triton X-100 were added to the buffer immediately before adding the cells. Cells were lysed by sonication while keeping the lysis mixture cool with an ice͞salt bath. The lysate was cleared of cellular debris by centrifugation at 12,851 ϫ g at 4°C for 45 min and then analyzed on 16.5% Tris-Tricine gel.
Purification of Mutant Calbindin D9k. The lysate was poured into a 50-ml conical tube containing 3 ml of NiNTA Superflow (Qiagen) as a 50% slurry in lysis buffer (see above). The mixture was rocked for 1 h at 4°C. The slurry was packed into a 1.5-cm-diameter column, and flow-through was collected. The column was washed with 10 bed volumes of lysis buffer. The bound protein was eluted with lysis buffer containing 150 mM imidazole. Protein levels in the effluent were monitored. A 20-ml volume was collected at the peak protein concentration and dialyzed two times against 2 liters of 20 mM Tris⅐HCl, pH 8.0͞1 mM EDTA͞1 mM DTT͞20% glycerol͞ 0.02% sodium azide. After dialysis, the solution was filtered through a 0.45-m filter and loaded onto a 2.5 ϫ 5.7-cm column of Q-Sepharose (GE Healthcare Bio-Sciences) equilibrated with the dialysis buffer. We found that the mutant calbindin D 9k does not bind to Q-Sepharose and appears as a single protein in a flowthrough (verified by SDS͞PAGE), whereas contaminating proteins do bind to Q-Sepharose and could be eluted with a gradient buffer (0-500 mM NaCl͞20 mM Tris⅐HCl, pH 8.0͞1 mM EDTA). After washing the Q-Sepharose column with dialysis buffer until all nonbound mutant calbindin D 9k was eluted, these fractions were collected and analyzed on 15% Tris-glycine gel. After SDS͞PAGE, the pooled fractions containing pure mutant calbindin D 9k (40 ml total) were brought to a final concentration of 25 mM Ca 2ϩ by the addition of 2.0 M CaCl 2 , transferred to a 6.4 ml͞cm 3,500 molecular weight cutoff Spectra͞POR molecular porous membrane tube (Spectrum Medical Industries, Los Angeles, CA), and concentrated against PEG 2000 flakes. After 7 h, the sample was dialyzed overnight in 2 liters of buffer containing 25 mM Tris⅐HCl (pH 8.0), 25 mM CaCl 2 , 0.02% sodium azide, and 20% glycerol. The protein was concentrated further by using PEG 2000 flakes and then dialyzed overnight against a buffer containing 25 mM Tris⅐HCl (pH 8.0), 25 mM CaCl 2 , 20% glycerol, and 0.02% sodium azide. After dialysis, the total protein concentration was determined by the Bradford assay (26) .
